Sana Biotechnology (SANA) vs Tectonic Therapeutic (TECX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Tectonic Therapeutic (TECX) has outperformed Sana Biotechnology (SANA) over the past year, gaining 8.1% versus a loss of 51.7%. Over five years, TECX leads with a -57.7% price change compared with -91.3% for SANA. Sana Biotechnology is the larger company by market cap ($476.4 million vs $405.3 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SANA | TECX |
|---|---|---|
| Share price | $1.59 | $20.73 |
| Market cap | $476.42M | $405.26M |
| 1-day change | -8.62% | -1.47% |
| YTD return | -60.93% | -0.62% |
| 1-year return | -51.67% | +8.08% |
| 5-year return | -91.34% | -57.66% |
| EPS (TTM) | $-0.52 | $-4.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-244.17M | $-74.15M |
| 52-week high | $5.49 | $39.53 |
| 52-week low | $1.57 | $16.77 |
| Distance from 52-week high | -71.04% | -47.56% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +438.99% | +242.50% |
| Average volume | 3.30M | 212.16K |
| Shares outstanding | 299.63M | 19.55M |
| Employees | 142 | 60 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TECX has outperformed SANA by 59.8 percentage points over the past year.
About Sana Biotechnology
SANA stock →Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 142 employees
About Tectonic Therapeutic
TECX stock →Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees
SANA vs TECX FAQ
Which is bigger, Sana Biotechnology or Tectonic Therapeutic?
Sana Biotechnology (SANA) is larger, with a market capitalization of $476.42M compared with $405.26M for Tectonic Therapeutic (TECX).
Which stock has performed better over the past year, SANA or TECX?
TECX returned +8.08% over the past 12 months, compared with -51.67% for SANA (price return, excluding dividends). Past performance does not predict future results.
Are Sana Biotechnology and Tectonic Therapeutic in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.